- Home
- DTIL vs CCIF Comparison
DTIL vs CCIF Comparison
Compare DTIL & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTIL | CCIF |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 84.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | DTIL | CCIF |
|---|---|---|
| Price | $3.90 | $3.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | ★ 214.9K | 76.9K |
| Earning Date | 03-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 25.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $698,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.53 | $7.43 |
| 52 Week High | $8.82 | $10.16 |
Technical Indicators
Market Signals| Indicator | DTIL | CCIF |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 26.67 |
| Support Level | $3.62 | $3.97 |
| Resistance Level | $4.11 | $4.20 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 53.73 | 11.68 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.